We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+56.06%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$630M
AUM Growth
+$61.5M
Cap. Flow
-$103M
Cap. Flow %
-16.29%
Top 10 Hldgs %
88.37%
Holding
28
New
1
Increased
5
Reduced
1
Closed
12

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$28.1M
2
NUVL
Nuvalent
NUVL
+$19.8M
3
ATXS
Astria Therapeutics
ATXS
+$10.2M
4
AXSM icon
Axsome Therapeutics
AXSM
+$6.87M
5
VRNA
Verona Pharma
VRNA
+$2.62M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$31M
2
INSM icon
Insmed
INSM
+$28.8M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$24.3M
4
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$21.9M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
26
Instil Bio
TIL
$49.4M
– –
-33,695
Closed -$3.26M
PNT
27
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-2,833,950
Closed -$21.9M
BHVN
28
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-204,743
Closed -$31M
1
2

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return

Fairmount Funds Management's Q4 2022 Portfolio in Review

As of Q4 2022, Fairmount Funds Management held 28 positions worth $630M, up 11% from $569M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Fairmount Funds Management withdrew a net $103M in Q4 2022, closing 12 positions and reducing 1 holding. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $31M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

Against the trend, Fairmount Funds Management opened a new position in Enliven Therapeutics worth $2.58M.

  • Fairmount Funds Management's largest Q4 2022 buy was Enliven Therapeutics: 157,833 shares worth $2.58M.
  • Fairmount Funds Management added most to BeOne Medicines Ltd in Q4 2022, an estimated $28.1M increase.
  • Fairmount Funds Management's biggest Q4 2022 reduction was Terns Pharmaceuticals, cutting an estimated $66.6K.
  • Fairmount Funds Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $31M.
  • Fairmount Funds Management's ten largest holdings make up 88% of its $630M portfolio in Q4 2022.
  • Fairmount Funds Management opened 1 new position and closed 12 in Q4 2022.
  • Fairmount Funds Management's portfolio value rose 11% quarter-over-quarter to $630M.

Based on Fairmount Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.